The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
A hypoxia-inducible factor prolyl hydroxylase inhibitor: roxadustat
Author(s): 
Pages: 551-556
Year: Issue:  4
Journal: World Phytomedicines

Keyword:  roxadustathypoxia-inducible factor prolyl hydroxylase inhibitorchronic kidney diseaseanemia;
Abstract: Anemia is one of the most important complications of chronic kidney disease(CKD). The prevalence of anemia also increases with the progression of CKD. Roxadustat is a novel oral hypoxia-inducible factor(HIF) prolyl hydroxylase inhibitor(PHI), which can induce the increase of erythropoietin. It can cure anemia and maintain the level of hemoglobin in CKD patients not yet receiving dialysis but also patients in end-stage renal disease receiving dialysis. Roxadustat is well tolerated, and may provide a safer and more convenient treatment for patients with CKD anemia.
Related Articles
No related articles found